DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Siltuximab is an investigational drug.
There have been 18 clinical trials for Siltuximab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2011.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Schizophrenia. The leading clinical trial sponsors are Janssen Research & Development, LLC, Centocor, Inc., and Brian Miller.
There are eleven US patents protecting this investigational drug and four hundred and twenty-six international patents.
Recent Clinical Trials for Siltuximab
|Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease||University of Pennsylvania||Phase 2|
|Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis||Janssen Scientific Affairs, LLC||Phase 2|
|Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis||Memorial Sloan Kettering Cancer Center||Phase 2|
Top disease conditions for Siltuximab
Top clinical trial sponsors for Siltuximab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Siltuximab||See Pricing||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||See Pricing|
|Siltuximab||See Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Pricing|
|Siltuximab||See Pricing||Disulfur bridge linkers for conjugation of a cell-binding molecule||HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)||See Pricing|
|Siltuximab||See Pricing||Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule||HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)||See Pricing|
|Siltuximab||See Pricing||P97 fragments with transfer activity||biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Siltuximab||European Patent Office||2954056||2033-02-08||See Pricing|
|Siltuximab||Hong Kong||1218930||2033-02-08||See Pricing|
|Siltuximab||World Intellectual Property Organization (WIPO)||2014124326||2033-02-08||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|